These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29975972)

  • 1. A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression.
    Severus E; Sauer C; Bauer M; Ostacher M; Anghelescu IG
    Pharmacopsychiatry; 2019 Jul; 52(4):170-174. PubMed ID: 29975972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression.
    Severus E; Seemüller F; Berger M; Dittmann S; Obermeier M; Pfennig A; Riedel M; Frangou S; Möller HJ; Bauer M
    BMC Med; 2012 Jul; 10():67. PubMed ID: 22747667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing antidepressant maintenance methodologies.
    Safer DJ
    Contemp Clin Trials; 2017 Oct; 61():87-95. PubMed ID: 28739537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.
    Faries DE; Heiligenstein JH; Tollefson GD; Potter WZ
    J Clin Psychopharmacol; 2001 Dec; 21(6):561-8. PubMed ID: 11763002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving study design for antidepressant effectiveness assessment.
    Naudet F; Millet B; Reymann JM; Falissard B
    Int J Methods Psychiatr Res; 2013 Sep; 22(3):217-31. PubMed ID: 24038333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.
    Fishbain DA; Detke MJ; Wernicke J; Chappell AS; Kajdasz DK
    Curr Med Res Opin; 2008 Nov; 24(11):3105-15. PubMed ID: 18828958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo group needed for interpretation of combination trial.
    El-Mallakh RS; Kaur G; Lippman S
    Am J Psychiatry; 2010 Aug; 167(8):996; author reply 996-7. PubMed ID: 20693473
    [No Abstract]   [Full Text] [Related]  

  • 18. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI; Martinson MA; Fava M; Iovieno N
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
    Mancini M; Wade AG; Perugi G; Lenox-Smith A; Schacht A
    J Psychiatr Res; 2014 Apr; 51():21-9. PubMed ID: 24462042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.